Search
Procaine benzylpenicillin
go.drugbank.com/drugs/DB09320ApprovedVet approvedProcaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic.
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigationalIn addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]
Cevimeline
go.drugbank.com/drugs/DB00185ApprovedCevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.
Voretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigational[A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … This type of virus is vastly used as vectors for gene therapy because they can infect dividing and quiescent cell integrating just the carried genes into the host genome without fully integrating into
Methane
go.drugbank.com/drugs/DB15994InvestigationalMixtures: iCOmas 0,3 % / 0,3 % / 0,3 % Gas zur medizinischen Anwendung, druckverdichtetGadobenic acid
go.drugbank.com/drugs/DB00743ApprovedInvestigational[A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166] … [A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.
Ivabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalTherefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing … Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label].
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … Florquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer.
V24343
go.drugbank.com/drugs/DB05201InvestigationalThe anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedEftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.